DBV Technologies to Participate in Upcoming March Investor Conferences
Rhea-AI Summary
DBV Technologies (Nasdaq: DBVT) will participate in two investor events in March 2026: a fireside chat at Citizens Life Sciences Conference on March 10, 2026 at 1:40pm ET and one-on-one meetings at the Leerink Partners Global Healthcare Conference on March 11, 2026.
The Citizens presentation will be webcast live and a replay will be available on the company's Events page 90 days after the event.
Positive
- None.
Negative
- None.
Details
News Market Reaction – DBVT
In the Mar 5 session, DBVT declined 3.12%, reflecting a moderate negative market reaction.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
- Citizens Life Sciences Conference date
- March 10, 2026
- Investor conference participation
- Citizens fireside chat time
- 1:40pm ET
- Citizens Life Sciences Conference session
- Leerink conference date
- March 11, 2026
- Leerink Partners Global Healthcare Conference
- Webcast replay availability
- 90 days
- Replay on company website after Citizens conference
Historical Context
-
Additional positive VITESSE Phase 3 data for VIASKIN Peanut Patch in children.
-
CEO fireside chat at Guggenheim biotech summit with webcast access.
-
Disclosure of total shares and voting rights as of January 31, 2026.
-
€166.7M gross proceeds from full exercise of March 2025 warrants.
-
Updated total shares and voting rights as of December 31, 2025.
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
AI-generated analysis. How Rhea-AI works. Not financial advice.
Châtillon, France, March 4, 2026
DBV Technologies to Participate in Upcoming March Investor Conferences
DBV Technologies (Euronext: DBV – ISIN: FR0010417345 – Nasdaq Stock Market: DBVT), a late-stage biopharmaceutical company, today announced the company will participate at the following investor conferences in March:
Citizens Life Sciences Conference – March 10, 2026
Format: Fireside Chat
Time: 1:40pm ET
Leerink Partners Global Healthcare Conference – March 11, 2026
Format: 1 on 1 Meetings
Sign up to watch the live webcast of the Citizens JMP presentation here. A replay will also be available on the Events section of the Company's website 90 days after the event.
About DBV Technologies
DBV Technologies is a late-stage biopharmaceutical company developing treatment options for food allergies and other immunologic conditions with significant unmet medical need. DBV Technologies is currently focused on investigating the use of its proprietary VIASKIN® patch technology to address food allergies, which are caused by a hypersensitive immune reaction and characterized by a range of symptoms varying in severity from mild to life-threatening anaphylaxis. Millions of people live with food allergies, including young children. Through epicutaneous immunotherapy (EPIT), the VIASKIN® patch is designed to introduce microgram amounts of a biologically active compound to the immune system through intact skin. EPIT is a new class of non-invasive treatment that seeks to modify an individual’s underlying allergy by re-educating the immune system to become desensitized to allergen by leveraging the skin’s immune tolerizing properties. DBV Technologies is committed to transforming the care of food allergic people. The Company’s food allergy programs include ongoing clinical trials of VIASKIN Peanut in peanut allergic toddlers (1 through 3 years of age) and children (4 through 7 years of age).
DBV Technologies is headquartered in Châtillon, France, with North American operations in Warren, NJ. The Company’s ordinary shares are traded on segment B of Euronext Paris (DBV, ISIN code: FR0010417345) and the Company’s ADSs (each representing five ordinary shares) are traded on the Nasdaq Capital Market (DBVT – CUSIP: 23306J309).
For more information, please visit www.dbv-technologies.com and engage with us on X (formerly Twitter) and LinkedIn.
VIASKIN is a registered trademark of DBV Technologies.
Investor Contact
Jonathan Neely
DBV Technologies
Jonathan.neely@dbv-technologies.com
Media Contact
Brett Whelan
DBV Technologies
Brett.whelan@dbv-technologies.com
Attachment
